Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $301,738 | 69 | 49.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $216,648 | 87 | 35.7% |
| Travel and Lodging | $43,634 | 172 | 7.2% |
| Honoraria | $35,735 | 11 | 5.9% |
| Food and Beverage | $9,267 | 151 | 1.5% |
| Education | $335.04 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $112,213 | 131 | $0 (2024) |
| GENZYME CORPORATION | $89,455 | 44 | $0 (2024) |
| Novo Nordisk Inc | $86,036 | 47 | $0 (2024) |
| Shire North American Group Inc | $74,931 | 84 | $0 (2019) |
| CSL Behring | $64,839 | 41 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $47,597 | 29 | $0 (2023) |
| BIOVERATIV THERAPEUTICS INC. | $44,694 | 30 | $0 (2021) |
| BioMarin Pharmaceutical Inc. | $22,450 | 22 | $0 (2024) |
| Genentech USA, Inc. | $22,132 | 18 | $0 (2024) |
| HEMA Biologics, LLC | $18,960 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $73,220 | 66 | GENZYME CORPORATION ($18,508) |
| 2023 | $58,831 | 37 | GENZYME CORPORATION ($23,813) |
| 2022 | $106,551 | 72 | GENZYME CORPORATION ($28,753) |
| 2021 | $69,959 | 38 | Takeda Pharmaceuticals U.S.A., Inc. ($28,192) |
| 2020 | $45,459 | 28 | CSL Behring ($17,160) |
| 2019 | $94,319 | 95 | Bayer HealthCare Pharmaceuticals Inc. ($35,644) |
| 2018 | $69,497 | 46 | Bioverativ Therapeutics Inc. ($24,067) |
| 2017 | $89,522 | 118 | Shire North American Group Inc ($37,535) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $128.91 | General |
| 12/04/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,909.00 | General |
| Category: Hematology | ||||||
| 11/14/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Travel and Lodging | Cash or cash equivalent | $269.00 | General |
| Category: Hematology | ||||||
| 11/14/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $97.50 | General |
| Category: Hematology | ||||||
| 11/14/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $72.53 | General |
| Category: Hematology | ||||||
| 11/14/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Travel and Lodging | Cash or cash equivalent | $44.26 | General |
| Category: Hematology | ||||||
| 11/14/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $38.32 | General |
| Category: Hematology | ||||||
| 11/11/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $76.72 | General |
| Category: Hematology | ||||||
| 11/09/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Hematology | ||||||
| 11/09/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Travel and Lodging | Cash or cash equivalent | $8.60 | General |
| Category: Hematology | ||||||
| 11/08/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Food and Beverage | In-kind items and services | $100.75 | General |
| Category: Hematology | ||||||
| 11/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $8,776.25 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $500.10 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $281.37 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $262.68 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $48.00 | General |
| 10/30/2024 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $3,559.50 | General |
| 10/16/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,870.00 | General |
| Category: Hematology | ||||||
| 10/16/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,870.00 | General |
| Category: Hematology | ||||||
| 10/04/2024 | HEMA Biologics, LLC | SevenFact (Biological) | Travel and Lodging | Cash or cash equivalent | $457.96 | General |
| Category: Hematology | ||||||
| 09/27/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $6,648.00 | General |
| 09/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $224.23 | General |
| 09/05/2024 | BioMarin Pharmaceutical Inc. | ROCTAVIAN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $944.00 | General |
| Category: Hemophilia A | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 86 | 105 | $62,514 | $10,138 |
| 2022 | 4 | 101 | 119 | $66,291 | $12,060 |
| 2021 | 8 | 162 | 186 | $82,966 | $18,912 |
| 2020 | 10 | 176 | 194 | $59,288 | $14,529 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 38 | 50 | $32,314 | $5,021 | 15.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 20 | $13,985 | $2,683 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 35 | $16,215 | $2,434 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 51 | $29,625 | $5,332 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 40 | $16,892 | $2,730 | 16.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $10,125 | $2,294 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $9,649 | $1,703 | 17.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 41 | 51 | $25,071 | $5,924 | 23.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $15,354 | $3,105 | 20.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 19 | $12,831 | $2,989 | 23.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 23 | $10,513 | $2,450 | 23.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 26 | $9,608 | $1,911 | 19.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 21 | $5,115 | $1,186 | 23.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 13 | $1,714 | $814.79 | 47.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 11 | $2,760 | $533.50 | 19.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 20 | $12,615 | $3,222 | 25.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 30 | 31 | $3,685 | $1,964 | 53.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 14 | $6,002 | $1,531 | 25.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $7,250 | $1,485 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 15 | $4,827 | $1,244 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 19 | $4,348 | $1,099 | 25.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 25 | 28 | $2,177 | $1,065 | 48.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 19 | $6,481 | $1,014 | 15.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 14 | $6,463 | $987.76 | 15.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 23 | $5,440 | $917.37 | 16.9% |
About Dr. Mark Reding, MD
Dr. Mark Reding, MD is a Internal Medicine healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336223866.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Reding, MD has received a total of $607,358 in payments from pharmaceutical and medical device companies, with $73,220 received in 2024. These payments were reported across 500 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($301,738).
As a Medicare-enrolled provider, Reding has provided services to 525 Medicare beneficiaries, totaling 604 services with total Medicare billing of $55,639. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Minneapolis, MN
- Active Since 10/24/2006
- Last Updated 01/04/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336223866
Products in Payments
- ADVATE (Biological) $63,477
- Jivi (Drug) $50,033
- Idelvion (Biological) $38,741
- Kogenate FS (Drug) $27,667
- NO PRODUCT DISCUSSED (Drug) $26,370
- ALTUVIIIO (Biological) $21,706
- SevenFact (Biological) $18,879
- ELOCTATE (Biological) $14,059
- HEMGENIX (Biological) $12,775
- VONVENDI (Biological) $10,200
- ALPROLIX (Biological) $9,517
- Kovaltry (Drug) $8,518
- HEMLIBRA (Biological) $8,271
- ADYNOVATE (Biological) $8,052
- Hemlibra (Biological) $6,552
- Novoeight (Drug) $6,490
- ROCTAVIAN (Drug) $5,594
- Non-Covered Product (Drug) $5,280
- Non-Covered $5,047
- NovoSeven RT (Drug) $4,655
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Minneapolis
Dr. Jay Cohn, M.d, M.D
Internal Medicine — Payments: $924,540
Dr. Nedaa Skeik, Md, MD
Internal Medicine — Payments: $669,804
Wesley Pedersen, Md, MD
Internal Medicine — Payments: $595,626
Shilpa Gupta, Md, Mbbs, MD, MBBS
Internal Medicine — Payments: $528,257
Dr. Marshall Hertz, M.d, M.D
Internal Medicine — Payments: $398,078
Dr. David Ingbar, M.d, M.D
Internal Medicine — Payments: $218,426